Given these multiple roles, fetuin-A shows potential as a non-invasive serum biomarker for tracking changes in liver fat and metabolic homeostasis in response to pharmacological treatment of MASLD by monitoring its levels as a reflection of physiological responses. The gene discussed is AHSG; the disease is metabolic dysfunction-associated steatotic liver disease.